Zealand Pharma A/S/€ZEAL
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company focused on the discovery, design, and development of innovative peptide-based medicines. The company is headquartered in Copenhagen, Denmark, and operates in the pharmaceutical industry. Zealand Pharma's portfolio includes several marketed products and a robust pipeline addressing gastrointestinal, metabolic, and other specialty disease areas. Notably, their therapeutic offerings include dasiglucagon for severe hypoglycemia and other proprietary peptides. The company leverages its unique peptide platform to enhance drug discovery and development processes, aiming to deliver targeted treatments with potentially improved safety and efficacy profiles.
Ticker
€ZEAL
Sector
Primary listing
XGAT
Employees
491
Headquarters
Søborg, Denmark
Website
ZEAL Metrics
BasicAdvanced
€2.9bn
3.37
€12.07
0.57
-
Price and volume
Market cap
€2.9bn
Beta
0.57
52-week high
€74.26
52-week low
€30.50
Average daily volume
2.5k
Financial strength
Current ratio
23.565
Quick ratio
23.202
Long term debt to equity
2.583
Total debt to equity
2.736
Interest coverage (TTM)
238.04%
Profitability
EBITDA (TTM)
926.977
Gross margin (TTM)
99.99%
Net profit margin (TTM)
70.05%
Operating margin (TTM)
75.06%
Effective tax rate (TTM)
7.80%
Revenue per employee (TTM)
€2,511,800
Management effectiveness
Return on assets (TTM)
33.97%
Return on equity (TTM)
55.06%
Valuation
Price to earnings (TTM)
3.367
Price to revenue (TTM)
2.324
Price to book
1.47
Price to tangible book (TTM)
1.48
Price to free cash flow (TTM)
3.314
Free cash flow yield (TTM)
30.17%
Free cash flow per share (TTM)
12.267
Growth
Revenue change (TTM)
14,598.86%
Earnings per share change (TTM)
-655.54%
3-year revenue growth (CAGR)
345.83%
10-year revenue growth (CAGR)
47.61%
3-year earnings per share growth (CAGR)
51.36%
10-year earnings per share growth (CAGR)
33.70%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zealand Pharma A/S stock?
Zealand Pharma A/S (ZEAL) has a market cap of €2.9B as of May 04, 2026.
What is the P/E ratio for Zealand Pharma A/S stock?
The price to earnings (P/E) ratio for Zealand Pharma A/S (ZEAL) stock is 3.37 as of May 04, 2026.
Does Zealand Pharma A/S stock pay dividends?
No, Zealand Pharma A/S (ZEAL) stock does not pay dividends to its shareholders as of May 04, 2026.
When is the next Zealand Pharma A/S dividend payment date?
Zealand Pharma A/S (ZEAL) stock does not pay dividends to its shareholders.
What is the beta indicator for Zealand Pharma A/S?
Zealand Pharma A/S (ZEAL) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.